mlab20250728_8k.htm
false
0000724004
0000724004
2025-08-12
2025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 12, 2025
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Colorado
(State or other jurisdiction of
incorporation)
|
0-11740
(Commission File Number)
|
84-0872291 (I.R.S. Employer
Identification No.)
|
12100 WEST SIXTH AVENUE,
LAKEWOOD, Colorado
(Address of principal executive offices)
|
|
80228
(Zip Code)
|
Registrant’s telephone number, including area code: 303-987-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered under Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange on which
registered
|
|
|
|
|
|
Common Stock, no par value
|
|
MLAB
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.03 CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A REGISTRANT.
On August 12, 2025, Mesa Laboratories, Inc. ("the "Company") drew $97 million under its existing Credit Facility. As of the date of this report, $108 million is outstanding under the Credit Facility.
The proceeds from the draw were used to fund the settlement of the Company's outstanding convertible notes that matured on August 15, 2025 in accordance with the terms of the indenture governing the notes.
The Credit Facility bears interest at either a base rate or a SOFR rate, plus an applicable spread. The Credit Facility matures on April 5, 2029.
The description of the Credit Facility in this Item 2.03 is qualified entirely by reference to the full text of the senior secured credit agreement, a copy of which was filed with the Company's Current Report on Form 8-K filed on April 8, 2024 and is incorporated by reference herein.
ITEM 9.01 Financial Statements and Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: August 18, 2025
|
|
Mesa Laboratories, Inc.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
BY:
|
/s/ Gary M. Owens
|
|
|
Gary M. Owens
|
|
|
President and Chief Executive Officer
|